Development of technologies for sustained drug delivery is a topic of great interest among retina specialists considering the number of chronic conditions that are managed with repeated intravitreal injections.
Products in this category are already available, and several novel implants are being developed that have shown positive results in clinical trials.
“The future for sustained intravitreal drug delivery looks bright,” said Glenn J. Jaffe, MD, Robert Machemer Professor of Ophthalmology, Duke University Eye Center, Durham, NC, in an update during the Retina Subspecialty Day meeting.
“Innovation occurring in this field shows promise to provide ophthalmologists with access to implants that can be inserted in an office setting and that are adaptable to use with virtually any therapeutic agent,” he said. “Furthermore, the sustained-delivery system release characteristics can be tailored for a particular disease.”